RALEIGH, N.C., March 21, 2016 -- PRA Health Sciences (PRA) (NASDAQ:PRAH), a leading global contract research organization, is pleased to announce that it has been awarded a 2016 Top Workplaces honor by Philly.com. The Top Workplaces recognition is based solely on the results of an employee feedback survey administered by WorkplaceDynamics, LLC, a leading research firm that specializes in organizational health and workplace improvement.
“We are honored to receive this recognition,” said Tami Klerr, Executive Vice President, Business Development. “At PRA, our employees are what make our company great and it is affirming to see that they are proud of where they work. This award is a testament to the dedication and passion they bring to working in an industry that helps bring life-improving and lifesaving drugs to market.”
In 2015, employees from PRA’s Horsham and Fort Washington facilities relocated to a new state-of-the-art facility in Blue Bell, now the company’s largest office worldwide. PRA has invested more than $4 million in the Blue Bell expansion project and expects to create at least 250 new full-time jobs by the end of 2016. Based on the project’s significant economic impact, the Pennsylvania Department of Community and Economic Development provided PRA with a $750,000 Pennsylvania First Program grant.
“We are hiring in all major divisions, including clinical operations areas and corporate functions,” said Harris Koffer, President, Strategic Solutions Division. “The clinical research industry requires many unique skill sets and we are always looking to attract high caliber talent to join our exceptional team.”
PRA currently has approximately 150 open positions in Philadelphia and the surrounding area. Information about PRA career opportunities can be found at www.DiscoverYourPRA.com.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, or CROs, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and approximately 12,000 employees worldwide. Since 2000, PRA has performed approximately 3,300 clinical trials worldwide and has worked on more than 100 marketed drugs across several therapeutic areas. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 60 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



